{
  "run_id": "316e093e-1897-4aa5-a999-735be777b985",
  "prompt_variant_id": "4dfed09b-b55e-4a74-884d-3b3b3b4aeb2f",
  "api_config_name": "model_gpt_4o",
  "test_case_id": "breast_cancer_her2_positive",
  "start_time": "2025-09-01T18:22:38.573488",
  "end_time": "2025-09-01T18:22:41.339026",
  "duration_ms": 2761.197090148926,
  "success": true,
  "error_message": "",
  "entities_extracted": 20,
  "entities_mapped": 8,
  "extraction_completeness": 1.25,
  "mapping_accuracy": 0.7058823529411764,
  "precision": 0.75,
  "recall": 0.9375,
  "f1_score": 0.8333333333333334,
  "compliance_score": 1.0,
  "token_usage": 4017,
  "extracted_entities": [
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "Conditions",
        "position": 0,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "Conditions",
        "position": 27,
        "context_sentence": "Conditions: HER2-Positive Breast Cancer, Metastatic Breast Cancer",
        "section_name": "conditionsModule",
        "section_type": "conditions",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "inclusion criteria",
        "position": 28,
        "context_sentence": "Histologically confirmed HER2-positive metastatic breast cancer",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Measurable disease",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "inclusion criteria",
        "position": 78,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "RECIST 1.1",
      "type": "procedure",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.85,
      "source_context": {
        "section": "inclusion criteria",
        "position": 96,
        "context_sentence": "Measurable disease per RECIST 1.1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "ECOG performance status 0-1",
      "type": "demographic",
      "attributes": {
        "status": "positive",
        "value": "0-1",
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "inclusion criteria",
        "position": 122,
        "context_sentence": "ECOG performance status 0-1",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Adequate organ function",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.85,
      "source_context": {
        "section": "inclusion criteria",
        "position": 153,
        "context_sentence": "Adequate organ function",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Prior treatment with Trastuzumab Deruxtecan",
      "type": "exclusion",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "exclusion criteria",
        "position": 187,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Active brain metastases",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "exclusion criteria",
        "position": 230,
        "context_sentence": "Active brain metastases",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Pregnancy",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "exclusion criteria",
        "position": 257,
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "breastfeeding",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "exclusion criteria",
        "position": 268,
        "context_sentence": "Pregnancy or breastfeeding",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "Trastuzumab Deruxtecan",
      "type": "medication",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "exclusion criteria",
        "position": 212,
        "context_sentence": "Prior treatment with Trastuzumab Deruxtecan",
        "section_name": "eligibilityModule",
        "section_type": "eligibility",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-targeted therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 22,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-positive metastatic breast cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefSummary",
        "position": 58,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "trastuzumab-based therapy",
      "type": "medication",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "past"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "briefSummary",
        "position": 112,
        "context_sentence": "This study evaluates a novel HER2-targeted therapy in patients with HER2-positive metastatic breast cancer who have progressed on prior trastuzumab-based therapy.",
        "section_name": "descriptionModule",
        "section_type": "description",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "briefTitle",
        "position": 17,
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "HER2-Positive Metastatic Breast Cancer",
      "type": "condition",
      "attributes": {
        "status": "positive",
        "value": null,
        "unit": null,
        "temporal_context": "current"
      },
      "confidence": 0.95,
      "source_context": {
        "section": "officialTitle",
        "position": 38,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Therapy",
      "type": "medication",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.85,
      "source_context": {
        "section": "briefTitle",
        "position": 9,
        "context_sentence": "Study of Novel Therapy in HER2-Positive Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Novel Targeted Therapy",
      "type": "medication",
      "attributes": {
        "status": null,
        "value": null,
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.85,
      "source_context": {
        "section": "officialTitle",
        "position": 18,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    },
    {
      "text": "Phase III",
      "type": "temporal",
      "attributes": {
        "status": null,
        "value": "Phase III",
        "unit": null,
        "temporal_context": "future"
      },
      "confidence": 0.9,
      "source_context": {
        "section": "officialTitle",
        "position": 2,
        "context_sentence": "A Phase III Study of Novel Targeted Therapy in HER2-Positive Metastatic Breast Cancer",
        "section_name": "identificationModule",
        "section_type": "identification",
        "document_id": "unknown"
      }
    }
  ],
  "Mcode_mappings": [
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 0",
      "mapping_rationale": "The entity 'HER2-Positive Breast Cancer' is a specific type of cancer diagnosis, which maps directly to the Mcode element CancerCondition.",
      "id": "8a7a726f-2f63-4ae8-8b6d-c4a8621a731d",
      "llm_source_text_fragment": "Entity index 0",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 1",
      "mapping_rationale": "The entity 'Metastatic Breast Cancer' is a specific type of cancer diagnosis, which maps directly to the Mcode element CancerCondition.",
      "id": "c80a6d39-4069-4e5f-8107-e403b8e7babb",
      "llm_source_text_fragment": "Entity index 1",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-positive metastatic breast cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 2",
      "mapping_rationale": "The entity 'HER2-positive metastatic breast cancer' is a specific type of cancer diagnosis, which maps directly to the Mcode element CancerCondition.",
      "id": "d2621f1d-4cc8-456d-b825-2b1bed696010",
      "llm_source_text_fragment": "Entity index 2",
      "source_references": []
    },
    {
      "resourceType": "Observation",
      "Mcode_element": "ECOGPerformanceStatus",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "ecogperformancestatus",
        "display": "ECOGPerformanceStatus"
      },
      "value": "0-1",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 5",
      "mapping_rationale": "The entity 'ECOG performance status 0-1' directly corresponds to the Mcode element ECOGPerformanceStatus, which captures performance scores.",
      "id": "62625133-6048-4500-a1cc-b948380124da",
      "llm_source_text_fragment": "Entity index 5",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "Trastuzumab Deruxtecan",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 7",
      "mapping_rationale": "The entity 'Trastuzumab Deruxtecan' is a medication used in cancer treatment, mapping to the Mcode element CancerRelatedMedication.",
      "id": "a4cdd483-25a8-4f74-b6c8-4b9e3c955ca4",
      "llm_source_text_fragment": "Entity index 7",
      "source_references": []
    },
    {
      "resourceType": "MedicationStatement",
      "Mcode_element": "CancerRelatedMedication",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancerrelatedmedication",
        "display": "CancerRelatedMedication"
      },
      "value": "trastuzumab-based therapy",
      "mapping_confidence": 0.9,
      "source_text_fragment": "Entity index 12",
      "mapping_rationale": "The entity 'trastuzumab-based therapy' is a medication regimen used in cancer treatment, mapping to the Mcode element CancerRelatedMedication.",
      "id": "4c93e5c3-a0ec-4c64-a62d-0e4763914a98",
      "llm_source_text_fragment": "Entity index 12",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 13",
      "mapping_rationale": "The entity 'HER2-Positive Breast Cancer' is a specific type of cancer diagnosis, which maps directly to the Mcode element CancerCondition.",
      "id": "18e7473a-40d3-4dc0-bcb7-b9ed189d59b8",
      "llm_source_text_fragment": "Entity index 13",
      "source_references": []
    },
    {
      "resourceType": "Condition",
      "Mcode_element": "CancerCondition",
      "code": {
        "system": "http://hl7.org/fhir/us/Mcode",
        "code": "cancercondition",
        "display": "CancerCondition"
      },
      "value": "HER2-Positive Metastatic Breast Cancer",
      "mapping_confidence": 0.95,
      "source_text_fragment": "Entity index 14",
      "mapping_rationale": "The entity 'HER2-Positive Metastatic Breast Cancer' is a specific type of cancer diagnosis, which maps directly to the Mcode element CancerCondition.",
      "id": "60bd2a76-820b-4c6a-bab6-87d81aaa18f2",
      "llm_source_text_fragment": "Entity index 14",
      "source_references": []
    }
  ],
  "validation_results": {
    "valid": true,
    "errors": [],
    "warnings": [],
    "compliance_score": 1.0
  }
}